Cases
CourtFilingsPetition dateMore filters
Synthego’s Chapter 11 case has moved from plan prosecution into implementation after the court approved the genetics company’s liquidation plan, according to Law360. That is the key value-inflection point for professionals tracking the case: recoveries, claim treatment, wind-down mechanics, and any remaining disputed-reserve issues now shift from negotiation and confirmation risk to execution under the approved plan.
The approval also gives counterparties and claims buyers a cleaner read on the remaining case arc. Rather than monitoring for competing restructuring paths, the focus should move to effective-date conditions, distribution timing, claims reconciliation, and any post-confirmation litigation or asset-realization work that will determine final creditor outcomes.
Synthego announced that it is entering the molecular biology and clinical diagnostic reagents market, launching reagents for nucleic-acid amplification, detection, and quality control, according to PR Newswire. The release frames the expansion as part of the company’s post-restructuring operating plan after emerging from Chapter 11 as Synthego Holdings LLC under Perceptive Advisors.
That matters because the bankruptcy sale is no longer just a balance-sheet reset: Perceptive’s acquired platform is being repositioned toward diagnostics and clinical reagents, a potentially broader commercial market than Synthego’s legacy CRISPR research tools. The update follows the court-approved asset sale in the Synthego asset sale order, giving lenders, trade creditors, and other case followers a concrete read on the reorganized company’s first public growth strategy after the sale process.
Loading defined terms…